Jinhua Development Conference and Wucheng Development Conference
Release time:
2023-05-11
News from our newspaper On April 30 and May 1, the 3rd Jinhua Development Conference and the 2nd Wucheng Development Conference opened successively. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, won two major awards at the "Jinhua Development Outstanding Achievement Award" and "Wucheng Development Merit Award" at the two conferences, and participated in the Jinhua Life and Health Industry Summit roundtable and other activities.
The third Jinhua Development Conference takes "New Era, New Jinhua, New Development" as the theme. The vast number of local sages at home and abroad and people from all walks of life who care about and support the development of Jinhua gathered together to participate in the grand event. Since the reform and opening up, many outstanding Jinhua talents and "new Jinhua people" have made great contributions to Jinhua's economic and social development while starting and innovating. This conference has awarded a series of honorary awards such as "model figures", "outstanding achievements" and "outstanding contributions. Jiang Xiaomeng and other 10 entrepreneurs won the "Jinhua Development Outstanding Achievement Award", and Xing Zhihong, deputy secretary of the Jinhua Municipal Party Committee and Mayor, presented awards to them. During the
Jinhua Development Conference, a series of activities such as investment signing and industry forum were also held. Jiang Xiaomeng participated in the Jinhua Life and Health Industry Summit Roundtable to discuss the future development of the health industry with relevant experts and entrepreneurs. In recent years, great changes have taken place in the pharmaceutical industry, especially policy adjustments such as drug review and approval reform and centralized procurement, which have brought challenges to the strategic direction and operation mode of pharmaceutical enterprises. In response to the topic of "how enterprises should respond to major changes in the current pharmaceutical industry", Jiang Xiaomeng put forward the view of "conforming to the trend and constantly adjusting the dynamic adjustment of enterprise strategy and operation mode to adapt to the continuous changes in the market", and emphasized "innovation" in his speech ". He proposed that as a pharmaceutical company, it should increase innovation from the "three-pronged approach" of R & D, manufacturing, and sales. On the R & D side, we should continue to increase investment in R & D. On the one hand, we should devote ourselves to the research and development of innovative drugs and improved new drugs with clinical value oriented and completely independent intellectual property rights. On the other hand, we should actively develop differentiated varieties such as pediatric drugs, rare disease drugs and characteristic traditional Chinese medicine encouraged by the state. On the manufacturing side, production enterprises should "deeply understand" the whole industrial chain, realize the whole chain control of production costs from raw materials, intermediates to preparations, and constantly improve the digital intelligence level of enterprises, improve labor productivity, and reduce the cost in the production and manufacturing process, so as to gain competitive advantage in the extreme competitive environment and seize the opportunity in centralized procurement. On the sales side, enterprises should not only aim at the domestic market, but also actively "go out to sea", build an international marketing team, and strive to open up the high-end markets in Europe, America and Japan and the "Belt and Road Initiative" market in Southeast Asia and Africa.
5# The second Wucheng Development Conference, which opened on September 1, took "New Journey, New Opportunity, New Wucheng" as the theme. The children of Wucheng at home and abroad gathered together to talk about Sangzi, narrate the feelings of the countryside, and seek the future together. The conference awarded a series of awards to those who have made outstanding contributions to the development of Wucheng. Jiang Xiaomeng and other 10 well-known entrepreneurs in Wucheng won the "Wucheng Development Merit Award".
"'Jinhua Development Outstanding Achievement Award' and' Wucheng Development Merit Award' are two very important awards, but this honor should belong to all peak people." In an interview with our reporter, Chairman Jiang Xiaomeng emphasized, "The reason why I can win these two awards is because of the healthy development of the peak in recent years, and the contribution to the social and economic development of Jinhua and Wucheng. The city and Wucheng district party committees, government departments, and all sectors of society have affirmed, and the current good development of the peak is the result of the joint efforts of the group's management teams at all levels and all employees. At present, we are facing an unprecedentedly complex market environment. We have to meet many difficulties and challenges. As a peak person, we should unite and redouble our efforts, continue to work hard and forge ahead, and repay the high hopes of Jinhua and Wucheng folks with better business performance." (Reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page